Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents

Lipton, A., Smith, M.R., Fizazi, K. et al. (8 more authors) (2016) Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. Clinical Cancer Research, 22 (23). pp. 5713-5721. ISSN 1078-0432

Abstract

Metadata

Authors/Creators:
  • Lipton, A.
  • Smith, M.R.
  • Fizazi, K.
  • Stopeck, A.T.
  • Henry, D.
  • Brown, J.
  • Shore, N.D.
  • Saad, F.
  • Spencer, A.
  • Zhu, L.
  • Warner, D.J.
Copyright, Publisher and Additional Information: © 2016 American Association for Cancer Research. This is an author produced version of a paper subsequently published in Clinical Cancer Research. Uploaded in accordance with the publisher's self-archiving policy
Keywords: Bone-specific alkaline phosphatase; bone turnover marker; denosumab; overall survival; urinary N-telopeptide
Dates:
  • Accepted: 11 April 2016
  • Published (online): 2 May 2016
  • Published: 1 November 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 01 Jul 2016 15:16
Last Modified: 18 Jul 2017 04:34
Published Version: https://dx.doi.org/10.1158/1078-0432.CCR-15-3086
Status: Published
Publisher: American Association for Cancer Research
Identification Number: https://doi.org/10.1158/1078-0432.CCR-15-3086

Share / Export

Statistics